SUMMIT THERAPEUTICS INC (SMMT)
US86627T1088 - Common Stock
SMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024
Summit Therapeutics just reported results for the first quarter of 2024.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
Notable Thursday Option Activity: SMMT, MRNA, GME
Top Buys by Top Brass: Chief Executive Officer Zanganeh's $421.4K Bet on SMMT
Snatch This Deal Even Lower Than Chief Executive Officer Zanganeh Did
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided...
Commit To Buy Summit Therapeutics At $3, Earn 24.6% Annualized Using Options
Why Summit Therapeutics Stock Crushed the Market This Week
The company was a standout in the biotech field, rising by nearly 23% over the period.
Thursday 3/28 Insider Buying Report: SMMT, EPSN
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such...
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such...
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Summit Therapeutics stock plunges 28% amid financial updates (NASDAQ:SMMT)
Shares of Summit Therapeutics plunged 28% after Q4 earnings report, mixed shelf registration filing, and extension of cash runway disclosed.
Summit Therapeutics Non-GAAP EPS of -$0.04 (NASDAQ:SMMT)
Summit Therapeutics' Q4 Non-GAAP EPS is -$0.04. The company extends $100 million note and updates cash guidance, now able to operate till Q1 2025.
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
Insider Bets Paying Off At SMMT As New 52-Week High Reached
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
